Cost-effectiveness of icosapent ethyl, evolocumab, alirocumab, ezetimibe, or fenofibrate in combination with dtatins compared to statin monotherapy
Despite treatment with statins, dyslipidaemia patients with elevated cholesterol- and triglyceride-levels remain at high residual risk for major adverse cardiovascular events (MACE). New lipid-lowering drugs must prevent the occurrence of MACE and exhibit cost-effectiveness for their successful adop...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
11 July 2022
|
| In: |
Clinical drug investigation
Year: 2022, Jahrgang: 42, Heft: 8, Pages: 643-656 |
| ISSN: | 1179-1918 |
| DOI: | 10.1007/s40261-022-01173-3 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s40261-022-01173-3 Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1007/s40261-022-01173-3 
|
| Verfasserangaben: | Daniel Tobias Michaeli, Julia Caroline Michaeli, Tobias Boch, Thomas Michaeli |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1867437376 | ||
| 003 | DE-627 | ||
| 005 | 20240307082649.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231024s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40261-022-01173-3 |2 doi | |
| 035 | |a (DE-627)1867437376 | ||
| 035 | |a (DE-599)KXP1867437376 | ||
| 035 | |a (OCoLC)1425216467 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Michaeli, Daniel |d 1997- |e VerfasserIn |0 (DE-588)1277183244 |0 (DE-627)1830345109 |4 aut | |
| 245 | 1 | 0 | |a Cost-effectiveness of icosapent ethyl, evolocumab, alirocumab, ezetimibe, or fenofibrate in combination with dtatins compared to statin monotherapy |c Daniel Tobias Michaeli, Julia Caroline Michaeli, Tobias Boch, Thomas Michaeli |
| 264 | 1 | |c 11 July 2022 | |
| 300 | |a 14 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 24.10.2023 | ||
| 520 | |a Despite treatment with statins, dyslipidaemia patients with elevated cholesterol- and triglyceride-levels remain at high residual risk for major adverse cardiovascular events (MACE). New lipid-lowering drugs must prevent the occurrence of MACE and exhibit cost-effectiveness for their successful adoption to clinical practice. | ||
| 700 | 1 | |a Michaeli, Julia |d 1996- |e VerfasserIn |0 (DE-588)127911424X |0 (DE-627)1832296377 |4 aut | |
| 700 | 1 | |a Boch, Tobias |d 1984- |e VerfasserIn |0 (DE-588)1052922015 |0 (DE-627)789313847 |0 (DE-576)40866732X |4 aut | |
| 700 | 1 | |a Michaeli, Christoph T. |d 1992- |e VerfasserIn |0 (DE-588)1277182337 |0 (DE-627)1830343769 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical drug investigation |d Berlin [u.a.] : Springer, 1989 |g 42(2022), 8 vom: Aug., Seite 643-656 |h Online-Ressource |w (DE-627)327645083 |w (DE-600)2043793-6 |w (DE-576)273880837 |x 1179-1918 |7 nnas |a Cost-effectiveness of icosapent ethyl, evolocumab, alirocumab, ezetimibe, or fenofibrate in combination with dtatins compared to statin monotherapy |
| 773 | 1 | 8 | |g volume:42 |g year:2022 |g number:8 |g month:08 |g pages:643-656 |g extent:14 |a Cost-effectiveness of icosapent ethyl, evolocumab, alirocumab, ezetimibe, or fenofibrate in combination with dtatins compared to statin monotherapy |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s40261-022-01173-3 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://link.springer.com/article/10.1007/s40261-022-01173-3 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20231024 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 1277182337 |a Michaeli, Christoph T. |m 1277182337:Michaeli, Christoph T. |d 60000 |d 61400 |d 60000 |d 63600 |e 60000PM1277182337 |e 61400PM1277182337 |e 60000PM1277182337 |e 63600PM1277182337 |k 0/60000/ |k 1/60000/61400/ |k 0/60000/ |k 1/60000/63600/ |p 4 |y j | ||
| 998 | |g 1052922015 |a Boch, Tobias |m 1052922015:Boch, Tobias |d 60000 |d 61200 |e 60000PB1052922015 |e 61200PB1052922015 |k 0/60000/ |k 1/60000/61200/ |p 3 | ||
| 998 | |g 127911424X |a Michaeli, Julia |m 127911424X:Michaeli, Julia |d 60000 |e 60000PM127911424X |k 0/60000/ |p 2 | ||
| 998 | |g 1277183244 |a Michaeli, Daniel |m 1277183244:Michaeli, Daniel |d 60000 |e 60000PM1277183244 |k 0/60000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1867437376 |e 4396111053 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 24.10.2023"],"title":[{"title":"Cost-effectiveness of icosapent ethyl, evolocumab, alirocumab, ezetimibe, or fenofibrate in combination with dtatins compared to statin monotherapy","title_sort":"Cost-effectiveness of icosapent ethyl, evolocumab, alirocumab, ezetimibe, or fenofibrate in combination with dtatins compared to statin monotherapy"}],"person":[{"role":"aut","display":"Michaeli, Daniel","family":"Michaeli","given":"Daniel"},{"family":"Michaeli","given":"Julia","display":"Michaeli, Julia","role":"aut"},{"role":"aut","display":"Boch, Tobias","family":"Boch","given":"Tobias"},{"role":"aut","display":"Michaeli, Christoph T.","family":"Michaeli","given":"Christoph T."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"11 July 2022"}],"physDesc":[{"extent":"14 S."}],"language":["eng"],"id":{"eki":["1867437376"],"doi":["10.1007/s40261-022-01173-3"]},"recId":"1867437376","name":{"displayForm":["Daniel Tobias Michaeli, Julia Caroline Michaeli, Tobias Boch, Thomas Michaeli"]},"relHost":[{"note":["Gesehen am 23.04.14"],"pubHistory":["1.1989 -"],"title":[{"title":"Clinical drug investigation","title_sort":"Clinical drug investigation"}],"origin":[{"publisher":"Springer ; ADIS International","dateIssuedDisp":"1989-","publisherPlace":"Berlin [u.a.] ; Auckland","dateIssuedKey":"1989"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"part":{"text":"42(2022), 8 vom: Aug., Seite 643-656","issue":"8","year":"2022","extent":"14","pages":"643-656","volume":"42"},"physDesc":[{"extent":"Online-Ressource"}],"disp":"Cost-effectiveness of icosapent ethyl, evolocumab, alirocumab, ezetimibe, or fenofibrate in combination with dtatins compared to statin monotherapyClinical drug investigation","language":["eng"],"id":{"zdb":["2043793-6"],"issn":["1179-1918"],"eki":["327645083"]},"recId":"327645083"}]} | ||
| SRT | |a MICHAELIDACOSTEFFECT1120 | ||